ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Lung Cancer MORE >>

According to results from an ongoing trial presented at the 2018 AACR Annual Meeting, adding atezolizumab to chemotherapy and an angiogenesis inhibitor led to significant improvement in progression-free survival for patients with untreated advanced nonsquamous non–small cell lung cancer.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.